长期使用一种血清对面部皮肤的年轻化和预老化的疗效和耐受性。

Long-Term Efficacy and Tolerability of a Daily Serum for Rejuvenation and Prejuvenation of Facial Skin.

出版信息

J Drugs Dermatol. 2023 Sep 1;22(9):917-924. doi: 10.36849/JDD.7393.

Abstract

Onjectives: To evaluate the long-term efficacy and tolerance of an anti-aging daily serum (AADS) when used twice-daily over 12 weeks by women with moderate skin fatigue and overall photodamage. The treatment targeted rejuvenation and prejuvenation of the facial skin. Method: This was an institutional review board (IRB)-approved, randomized, single-center, double-blinded, vehicle-controlled (VC) study involving healthy subjects. Seventy female subjects were recruited aged 30 to 60 years old, Fitzpatrick skin types I to VI, with moderate overall photodamage, facial skin dullness, and skin firmness. Subjects underwent a 1-week washout period with a skincare regimen consisting of a cleanser, moisturizer, and sunscreen. Subjects were randomized to apply the AADS or VC to their face including upper eyelid, twice-daily for 12 weeks. Long-term efficacy and tolerance, self-assessment questionnaire, and VISIA® clinical photography were performed at baseline, weeks 4, 8, and 12. Results: Statistically significant improvements in live, clinically graded efficacy parameters were demonstrated at post-baseline timepoints. Facial skin firmness, radiance, and roughness showed the most significant improvements at week 12. Analysis between treatments, in both live and photo-graded parameters, demonstrated merit of the AADS. VISIA® analysis further substantiated the efficacy of the AADS vs the VC. The AADS was well tolerated by clinical scoring and rating by subjects. Conclusion: The AADS is effective in improving skin fatigue and overall photodamage after 12 weeks of twice-daily application compared with the VC. The AADS is a possible skincare solution for patients seeking a serum with skin rejuvenation and prejuvenation benefits. Citation: Reid L, Palm MD, Kononov T, et al. Long-term efficacy and tolerability of a daily serum for rejuvenation and prejuvenation of facial skin. J Drugs Dermatol. 2023;22(9):917-924. doi:10.36849/JDD.7393.

摘要

目的

评估一种抗衰老日用血清（AADS）在 12 周内每天使用两次时对中度皮肤疲劳和整体光损伤女性的长期疗效和耐受性。该治疗针对面部皮肤的年轻化和预老化。

方法

这是一项机构审查委员会（IRB）批准的、随机的、单中心、双盲、对照（VC）研究，涉及健康受试者。招募了 70 名年龄在 30 岁至 60 岁之间、Fitzpatrick 皮肤类型 I 至 VI、整体光损伤中度、面部皮肤暗沉和皮肤紧致度下降的女性受试者。受试者在使用包含清洁剂、保湿霜和防晒霜的护肤方案进行为期 1 周的洗脱期后，随机接受 AADS 或 VC 涂抹于面部（包括上眼睑），每天两次，持续 12 周。在基线、第 4、8 和 12 周时进行长期疗效和耐受性、自我评估问卷和 VISIA®临床摄影。

结果

与基线相比，在后续时间点，有统计学意义的活体验效参数得到显著改善。在第 12 周时，面部皮肤紧致度、光泽度和粗糙度显示出最显著的改善。在活体验效和照片分级参数方面，治疗之间的分析均证明了 AADS 的优势。VISIA®分析进一步证实了 AADS 与 VC 相比的疗效。AADS 经临床评分和受试者评分均得到良好耐受。

结论

与 VC 相比，AADS 在每天使用两次、持续 12 周后可有效改善皮肤疲劳和整体光损伤。AADS 可能是一种治疗方案，为寻求具有皮肤年轻化和预老化功效的血清的患者提供帮助。

参考文献

Reid L, Palm MD, Kononov T, et al. Long-term efficacy and tolerability of a daily serum for rejuvenation and prejuvenation of facial skin. J Drugs Dermatol. 2023;22(9):917-924. doi:10.36849/JDD.7393.